Program
HS-20118
A development code.
In Hansoh Pharmaceutical Group's pipeline, oral IL-23R
. Its studies are mostly in Psoriasis, led by Hansoh Pharmaceutical Group.
Furthest: phase 2, since Aug 11, 20264 company-led studies, 3 open or runningNext primary completion: Dec 25, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 43 open or running | phase 2since Aug 11, 2026 | Feb 12, 2025 | Dec 25, 2026phase 1 · NCT07896915 |
- Named in Hansoh Pharmaceutical Group’s own pipeline as
HS-20118 (oral IL-23R)
, phase 2, as of Aug 26, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 12, 2025First study: phase 1 study in PsoriasisFirst studyNCT06846710 · 60 enrolled · United States, New Zealand
- Jun 3, 2025Phase 1 study in PsoriasisNCT07033234 · 142 planned · China
- Aug 11, 2026Phase 2 study in Moderate to Severe Plaque PsoriasisPhase 2 reachedNCT07765628 · 120 planned
- Oct 13, 2026Phase 1 study in Healthy ParticipantsNCT07896915 · 32 enrolled · China
Ahead
- Dec 25, 2026Primary completion: phase 1 study in Healthy ParticipantsNCT07896915
- Feb 28, 2027Primary completion: phase 2 study in Moderate to Severe Plaque PsoriasisNCT07765628
TargetBeta
“oral IL-23R”the company's pipeline, read by Claude · source
Other programs on IL23R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ABBV-859 | AbbVie | phase 1 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07896915Healthy Participants · China | 1 | Active, not recruiting | Dec 25, 2026 | 32 |
| NCT07765628Moderate to Severe Plaque Psoriasis | 2 | Not yet recruiting | Feb 28, 2027 | 120 |
| NCT07033234Psoriasis · China | 1 | Recruiting | Mar 2026 | 142 |
| NCT06846710Psoriasis · United States, New Zealand | 1 | Completed | Jul 14, 2026 | 60 |
How it is read
Names in the registry
- “HS-20118”, 5 entries
Codes read as this program: HS20118.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.